MFAP2

Across TCGA pan-cancer cohorts, MFAP2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MFAP2 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MFAP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MFAP2 expression acts as an unfavorable survival marker.

CCRCC, PDAC, and LSCC are the cancer types where MFAP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.589	0.893	.001	49	view →
PDAC	DFS	Tertile	II,III,IV	0.554	0.907	<.001	40	view →
LSCC	DFS	Quartile	All	0.564	0.859	.004	19	view →
HNSC	OS	Tertile	IV	0.625	0.882	.016	10	view →
LUAD	DFS	Median	II,III,IV	0.373	0.640	.031	7	view →
GBM	DFS	Quartile	All	0.270	0.558	.006	7	view →
UCEC	DFS	Median	All	0.857	0.953	.029	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MFAP2–CCRCC (DFS)

Open the CCRCC breakdown →